Virtual Library
Start Your Search
Jiangnan Feng
Author of
-
+
P15 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Novel Immunotherapeutics (Phase I) (ID 154)
- Event: WCLC 2020
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P15.09 - A Promising Result of Two Therapeutic Peptides Combined with Chemotherapy in the Treatment of Advanced NSCLC. (ID 798)
00:00 - 00:00 | Presenting Author(s): Jiangnan Feng
- Abstract
Introduction
H1 and H2 are therapeutic peptides with 15 and 12 amino acids, respectively. Their mechanisms of drug action are not yet fully clear. Pre-clinical research data have demonstrated that H1 and H2 result in inhibiting tumors and no toxic side effects with extreme doses. This study is only a record data of compassionate drugs use for advanced non-small cell lung cancer (NSCLC), not a standardized clinical trial.
Methods
Patients were included if they were diagnosed with adenocarcinoma and advanced NSCLC, the survival period was estimated at approximately 3 months, or the patients gave up anti-cancer treatment.
Patients were delivered 20mg each of H1 and H2 intravenously every day and instead once every three days after one year. An additional 4mg of H1 was given intravenously every 4 hours for patients with severe cancerous pain.
Chemotherapy was added for patients who were improved physical condition after treatment of H1 and H2. The chemotherapy regimen was taken paclitaxel-carboplatin and adopted up to four cycles.
The primary objective was to assess overall survival (OS). Some types of analysis were added due to an unexpected therapeutic effect.
Results
A total of 11 patients were treated with H1 and H2. Treatment-unrelated deaths occurred in three patients within twenty days after treatment. The 6-and 18-months of OS rates were 72% and 45%, respectively. The median OS reached 14.09 months. Objective response rate (ORR) was 72%, with 8 patients in stable disease (SD), with no partial response (PR) and no complete response (CR). The results showed that the size of tumor lesions failed to shrink after treatment of H1 and H2.
Four patients received additional chemotherapy during treatment of H1 and H2. ORR was 100%, with 2 patients in PR (50%) and 2 patients in CR (50%). As of this writing, none of four patients developed progressive disease (PD), and the duration of response (DOR) has reached 26, 34, 37, and 44 months, respectively.
Any toxicity and side effects were not observed except some interesting phenomena. Two patients with intense pain discontinued opioid analgesics after using H1. The patients treated, included three over 85 years of age, developed a change of hair from white to darkening.
Conclusion
The first results show that median survival period of advanced NSCLC patients treated with two therapeutic peptides alone has greatly prolonged from approximately 3 months to 14 months.
The effectiveness of chemotherapy is significantly improved when chemotherapy is used in combination with two therapeutic peptides. Compared to chemotherapy alone, ORR of combination therapy has increased from 30% to 100% and median DOR has increased from 3 months to at least 34 months. It is the incredible results that none of among all treated patients with advanced NSCLC have developed PD after a long period of time.
The surprise findings indicate that chemotherapy in combination with two therapeutic peptides may be a promising approach to treatment of NSCLC. However, the results with only four cases in total need to be interpreted with caution and have to be verified with more cases.
